[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"molar-third\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:molar-third":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100632294","phase-2-a-study-of-ly4515100-in-participants-with-pain-following-third-molar-removal-100632294",false,"NCT07511816","A Study of LY4515100 in Participants With Pain Following Third Molar Removal","A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of a Single Oral Dose of LY4515100, in Participants Experiencing Moderate-to-Severe Acute Pain Following Surgical Removal of Impacted Third Molars","Inclusion Criteria:\n\n* Participant has a body mass index (BMI) between 18.5 and 35.0 kilograms per meter squared (kg\u002Fm²) inclusive.\n* Participant requires extraction of 2 or more third molars, including 2 mandibular molars with partial or full bony impaction, confirmed by panoramic X-ray.\n\nExclusion Criteria:\n\n* Prior dental surgery within 60 days before screening or history of other surgical procedures that could confound surgery or postoperative procedures.\n* Diagnosis of chronic pain conditions that could confound postsurgical pain reporting in the opinion of the investigator.\n* Positive urine drug screen or alcohol test during screening or on the day of surgery.\n* Evidence or history of any other clinically significant hematological, renal, hepatic, endocrine, pulmonary, gastrointestinal, cardiovascular, psychiatric, or neurologic diseases, in the opinion of the investigator, within the last 5 years.\n* History of malignancy of any organ system treated or untreated, within 5 years prior to consent. The only exceptions are previous in situ carcinoma of the cervix, localized basal cell carcinoma of the skin, or localized squamous carcinoma of the skin if the participant has been treated and is considered cured.","ALL","18 Years","40 Years",{"count":20,"type":21},212,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this study is to evaluate the safety and efficacy of LY4515100 and see how a single oral dose compares with placebo in acute postsurgical pain after removing impacted third molars. For each participant, the study may last approximately 6 weeks and will include a stay in a Clinical Research Unit (CRU) after third molar removal.",[27,28,29,30],"Acute Pain","Molar","Molar, Third","Surgery, Oral","RECRUITING","2026-04-27",{"date":34,"type":35},"2026-05-01","ACTUAL",{"date":37,"type":35},"2026-04-01",{"date":39,"type":21},"2026-12",{"name":41,"class":42},"Eli Lilly and Company","INDUSTRY",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":43},"100565304","early-phase-1-led-therapy-for-third-molar-surgery-100565304","NCT06640439","LED Therapy for Third Molar Surgery","LED Therapy Using 830 Nm in the Mandibular Third Molar Surgery: Double-blind Randomized Clinical Trial.","LTTMS","Inclusion Criteria:\n\n1. Healthy Asians;\n2. 20-55 years old;\n3. Having mandibular third molars that are inappropriately erupted and need to be extracted due to caries, orthodontic reasons and\u002For periodontal disease;\n\nExclusion Criteria:\n\n1. Underlying diseases: diabetes, cardiovascular disease, coagulation disorder, osteoporosis, hypertension, neurological disease, psychological disorder, tumor, systemic infection or cyst at the extraction site;\n2. Women who are preparing for pregnancy, pregnant or breastfeeding;\n3. Medication history: use of analgesics, anti-inflammatory drugs and\u002For antibacterial drugs 2 weeks before tooth extraction, need for systemic medication other than acetaminophen after surgery, allergy to acetaminophen, use of anticoagulants, bisphosphonates;\n4. Bad habits, such as addicted to smoking, drinking, etc.;\n5. Volunteers who have recently participated in other clinical trials;","20 Years","55 Years",{"count":55,"type":21},50,[57],"EARLY_PHASE1","LED Therapy for third molar surgery",[29,60,61,62],"Photobiomodulation","Photobiomodulation Therapy","Third Molar Surgery",[64,65,66,67],"photobiomodulation","LED","830 nm","third molar surgery","NOT_YET_RECRUITING","2024-10-10",{"date":71,"type":35},"2024-10-15",{"date":73,"type":21},"2024-10-14",{"date":75,"type":21},"2025-04-14",{"name":77,"class":78},"Huashan Hospital","OTHER",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":4},"100550827","phase-4-evaluation-the-effect-of-coenzyme-q10-on-tissue-healing-process-in-patients-undergoing-wisdom-tooth-extraction-100550827","NCT06452134","Evaluation the Effect of Coenzyme Q10 on Tissue Healing Process in Patients Undergoing Wisdom Tooth Extraction","Evaluation the Effect of Coenzyme Q10 on Tissue Healing Process in Patients Undergoing Wisdom Tooth Extraction in the City of Sanandaj-Iran in 1402: a Double-blinded Clinical Trial Study","Inclusion Criteria:\n\n* Patients older than 18 years old that require mandibular or maxillary molar, third tooth extraction as Oral and Maxillofacial surgeon's clinical diagnosis.\n\nExclusion Criteria:\n\n* The patient's departure from Sanandaj\n* The patient's disagreement with the study protocol\n* The Patient's demise\n* The patient's hospitalization for unrelated illnesses\n* The patient's discontent with the care they received\n* The patient's failure to show up for follow-up appointments\n* The patient's sensitivity to Coenzyme Q10",{"count":87,"type":21},70,[89],"PHASE4","The goal of this clinical trial is to asses the effect of Coenzyme Q10 administration in patients from any gender group who are older than 18 years old undergoing wisdom tooth extraction. The main questions it aims to answer are:\n\ndoes Coenzyme Q10 help with better tissue healing? does Coenzyme Q10 administration lower the prevalence of Dry socket after surgery? does Coenzyme Q10 prevent TMD (Temporomandibular disorders) while recovering from surgery? how does Coenzyme Q10 administration effect the answers to SF-36 health survey in patients? Researchers will compare Coenzyme Q10 to a placebo (a look-alike substance that contains no drug) to see if it has any effect on mentioned parameters.\n\nParticipants will:\n\n* take coenzyme Q10 (100mg) daily for 30 days after surgery.\n* will be examined and evaluated 1, 7, 14 and 30 days after completion of surgery.",[29,92,93,94],"Temporomandibular Joint Disorders","Dry Socket","Coenzyme Q10",[96,93,92,29,97,98,99,100],"coenzyme Q10","SF-36 health survey","Tissue healing","Tooth Extraction","GHQ-12","2024-06-09",{"date":103,"type":35},"2024-06-11",{"date":105,"type":21},"2024-07",{"date":107,"type":21},"2025-05",{"name":109,"class":78},"Zahra Nejati"]